中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共49条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study 期刊论文
CANCER MEDICINE, 2022
作者:  Yu, Xiaoqing;  Si, Jinfei;  Wei, Jingwen;  Wang, Yanling;  Sun, Yan;  Jin, Jianan;  Zhang, Xiaoyan;  Ma, Tonghui;  Song, Zhengbo
收藏  |  浏览/下载：44/0  |  提交时间：2022/12/23
EGFR-TKIs  non-small cell lung cancer (NSCLC)  real-world study  survival outcome  
Hypoxia-inducible factor 1-alpha is a driving mechanism linking chronic obstructive pulmonary disease to lung cancer 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Xu, Yuan-rui;  Wang, An-long;  Li, Ya-qing
收藏  |  浏览/下载：42/0  |  提交时间：2022/12/23
chronic obstructive pulmonary disease  lung cancer  non-small cell lung cancer  hypoxia-inducible factor 1-alpha  hypoxia-inducible factor 1  
Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study 期刊论文
BMC PULMONARY MEDICINE, 2022, 卷号: 22
作者:  Wei, Jingwen;  Xiang, Jing;  Hao, Yue;  Si, Jinfei;  Wang, Wenxian;  Li, Fangyin;  Song, Zhengbo
收藏  |  浏览/下载：41/0  |  提交时间：2022/12/22
Anemia  Epidermal growth factor receptor  Epidermal growth factor receptor tyrosine kinase inhibitors  Non-small cell lung cancer  
Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety 期刊论文
JOURNAL OF THORACIC DISEASE, 2022
作者:  Shao, Lan;  Lou, Guangyuan
收藏  |  浏览/下载：44/0  |  提交时间：2022/12/22
Neoadjuvant  immunotherapy  immune-checkpoint inhibitors  non-small cell lung cancer (NSCLC)  
The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study 期刊论文
CANCERS, 2022, 卷号: 14
作者:  Xie, Mingying;  Li, Na;  Xu, Xiaoling;  Xu, Yanjun;  Li, Hui;  Zhu, Liang;  Sheng, Jiamin;  Zhou, Zichao;  Fan, Yun
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/22
liver metastasis  non-small cell lung cancer  PD-L1  PD-1  PD-L1 inhibitor  CD8+T cell  
Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Xu, X.;  Li, N.;  Fan, Y.
收藏  |  浏览/下载：38/0  |  提交时间：2022/12/23
ALK  non-small cell lung cancer (NSCLC)  leptomeningeal metastases (LM)  
Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2022, 卷号: 17
作者:  Lu, S.;  Jian, H.;  Zhang, Y.;  Song, Z.;  Zhao, Y.;  Wang, P.;  Jiang, L.;  Gong, Y.;  Zhou, J.;  Dong, X.;  Yang, N.;  Fang, J.;  Zhuang, W.;  Cang, S.;  Ma, R.;  Shi, J.;  Wu, P.;  Lu, J.;  Xiang, Z.;  Shi, Z.;  Zhang, L.;  Wang, Y.
收藏  |  浏览/下载：62/0  |  提交时间：2022/12/23
Non-small cell lung cancer  KRAS G12C mutation  Small molecular inhibitor  
Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Fu, Meng;  Feng, Chun-Mei;  Xia, Da-Qing;  Ji, Zi-Mei;  Xia, Huai-Ling;  Hu, Na-Na;  Leng, Zai-Jun;  Xie, Wang;  Fang, Yuan;  Cao, Le-Jie;  Zhang, Jun-Qiang
收藏  |  浏览/下载：37/0  |  提交时间：2022/12/23
savolitinib  MET exon 14 skipping  neoadjuvant therapy  non-small cell lung cancer  targeted therapy  
Sheep tail fat inhibits the proliferation of non-small-cell lung cancer cells in vitro and in vivo 期刊论文
FRONTIERS IN PHARMACOLOGY, 2022, 卷号: 13
作者:  Xu, Changzhi;  Zhang, Lanlan;  He, Huimin;  Liu, Xiaoyi;  Pei, Xinxin;  Ma, Tengfei;  Ma, Bingbing;  Lin, Wenchu;  Zhang, Buchang
收藏  |  浏览/下载：32/0  |  提交时间：2022/12/23
sheep tail fat  non-small-cell lung cancer  heptadecanoic acid  antiproliferative effect  Akt  S6K signaling pathway  
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong;  Yu, Xinmin;  Chen, Ming
收藏  |  浏览/下载：37/0  |  提交时间：2022/12/23
Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib